Related Experiment Video
Updated: Jun 13, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Bivalirudin during percutaneous coronary interventions in patients with ST segment elevation myocardial infarction
Insights
Bivalirudin shows promise as an anticoagulation treatment for ST elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI). This discussion covers key issues arising from its use in primary PCI procedures.
Area of Science:
- Cardiology
- Pharmacology
- Interventional Cardiology
Background:
- Bivalirudin, a direct thrombin inhibitor, is explored for its efficacy in anticoagulation.
- ST elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) are the focus population.
- The study examines the application of Bivalirudin in this specific clinical context.
Discussion:
- The use of Bivalirudin during primary PCI presents unique challenges and considerations.
- Potential complications and management strategies related to Bivalirudin in STEMI patients are reviewed.
- Clinical decision-making regarding anticoagulation choice in primary PCI is discussed.
Key Insights:
- Bivalirudin offers an alternative anticoagulation strategy in primary PCI for STEMI.
- Understanding the nuances of Bivalirudin administration is crucial for optimal patient outcomes.
- The discussion highlights areas requiring further investigation and clinical guidance.
Outlook:
- Further research may refine Bivalirudin's role in STEMI management.
- Clinical practice guidelines may evolve based on emerging evidence regarding direct thrombin inhibitors.
- Optimizing anticoagulation protocols remains a key objective in interventional cardiology.
Abstract:
Bivalirudin is a direct thrombin inhibitor that seems to be a promising anticoagulation treatment in patient with ST elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). We discuss several issues that were raised from the use of Bivalirudin during primary PCI.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Acute Coronary Syndrome I: Introduction
Peripheral Artery Disease III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
